

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 29 JUNE 2023

Reference is made to the circular of Genor Biopharma Holdings Limited (the “**Company**”) dated 29 April 2023 (the “**Circular**”). Unless the context otherwise requires, terms used in this announcement shall have the same meanings as defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

At the annual general meeting (the “**AGM**”) of the Company held on Thursday, 29 June 2023, all the proposed resolutions as set out in the notice of the AGM dated 29 April 2023 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and auditor (the “ Auditor ”) of the Company for the year ended 31 December 2022.	176,926,176 (100.000000%)	0 (0.000000%)
2.	(a) To re-elect Mr. Chen Yu as a non-executive Director.	176,560,051 (99.793063%)	366,125 (0.206937%)
	(b) To re-elect Mr. Liu Yi as a non-executive Director.	176,926,051 (99.999929%)	125 (0.000071%)
	(c) To re-elect Mr. Zhou Honghao as an independent non-executive Director.	176,708,726 (99.877096%)	217,450 (0.122904%)
	(d) To authorize the Board to fix the respective Directors’ remuneration.	176,926,176 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	To re-appoint PricewaterhouseCoopers as the Auditor for the year ending 31 December 2023 and to authorize the Board to fix their remuneration.	176,926,176 (100.000000%)	0 (0.000000%)
4.	To grant a general and unconditional mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	176,926,176 (100.000000%)	0 (0.000000%)
5.	To grant a general and unconditional mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	176,342,601 (99.670159%)	583,575 (0.329841%)
6.	Conditional upon resolutions numbered 4 and 5 being passed, to extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of shares repurchased by the Company.	176,342,601 (99.670159%)	583,575 (0.329841%)
Special Resolution		Number of Votes (%)	
		For	Against
7.	To approve the proposed amendments to the sixth amended and restated memorandum and articles of association of the Company and the adoption of the seventh amended and restated memorandum and articles of association of the Company.	176,926,176 (100.000000%)	0 (0.000000%)

As a majority of the votes were cast in favour of each of the ordinary resolutions numbered 2(a), 2(b), 2(c), 5 and 6, and all of the votes were cast in favour of each of the ordinary resolutions numbered 1, 2(d), 3 and 4, the resolutions were duly passed as ordinary resolutions.

As more than 75% of the votes were cast in favour of the special resolution numbered 7, the resolution was duly passed as special resolution.

As at the date of the AGM, the total number of shares of the Company in issue was 506,221,241 which represented the total number of Shares entitling the holder to attend and vote on the resolutions at the AGM. There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Listing Rules.

No Shareholder was required under the Listing Rules to abstain from voting on the resolutions at the AGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

All directors of the Company attended the AGM in person or by electronic means.

By Order of the Board
Genor Biopharma Holdings Limited
Dr. Guo Feng
Chief Executive Officer and Chairman

Hong Kong, 29 June 2023

As at the date of this announcement, the Board comprises Dr. GUO Feng as an executive director; Dr. LYU Dong, Mr. CHEN Yu and Mr. LIU Yi as non-executive directors; Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.